-
Product Insights
NewPrimary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2024
Empower your strategies with our Primary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Primary progressive multiple sclerosis (PPMS) is a rare and disabling form of MS that affects the brain, spinal cord, and optic nerves. Unlike other types of MS, PPMS does not have relapses or remissions, but causes steady worsening of neurological functions from the onset. PPMS affects about 10% of people with MS, and it occurs equally in men and...
-
Product Insights
NewPrader-Willi Syndrome (PWS) – Drugs In Development, 2024
Empower your strategies with our Prader-Willi Syndrome (PWS) – Drugs In Development, 2024 report and make more profitable business decisions. Prader-Willi syndrome (PWS) is a rare congenital genetic disorder that results in a number of physical, mental, and behavioral problems. PWS is due to the lack of several genes on one of an individual’s two chromosome 15s. In the majority of cases, there is a deletion. In the remaining cases, the entire chromosome from the father is missing and there are...
-
Product Insights
NewHigh-Grade Glioma – Drugs In Development, 2024
Empower your strategies with our High-Grade Glioma – Drugs In Development, 2024 report and make more profitable business decisions. High-grade gliomas (HGGs) are tumors of the central nervous system that arise from mutated cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, dysregulated appetite, paralysis, and seizures. Treatment includes chemotherapy and radiation therapy. The High-Grade Glioma drugs in development market research report provide...
-
Product Insights
NewMalignant Glioma – Drugs In Development, 2024
Empower your strategies with our Malignant Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant gliomas are aggressive and fast-growing tumors that arise from glial cells in the brain and spinal cord. Gliomas account for the most common type of primary brain tumors in adults. Symptoms of malignant gliomas vary depending on the tumor's size, location, and rate of growth. Common symptoms may include headaches, seizures, cognitive changes, personality or behavior changes, weakness or sensory loss,...
-
Product Insights
NewPancreatic Diseases – Drugs In Development, 2024
Empower your strategies with our Pancreatic Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Pancreatic diseases encompass a range of conditions that affect the pancreas, a vital organ located behind the stomach. The pancreas plays a crucial role in digestion and hormone regulation by producing enzymes for digestion and hormones like insulin and glucagon that regulate blood sugar levels. The Pancreatic Diseases drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewChikungunya Fever – Drugs In Development, 2024
Empower your strategies with our Chikungunya Fever – Drugs In Development, 2024 report and make more profitable business decisions. Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting, and rash and fever. Treatment includes use of non-steroidal...
-
Product Insights
NewPancreatitis – Drugs In Development, 2024
Empower your strategies with our Pancreatitis – Drugs In Development, 2024 report and make more profitable business decisions. Pancreatitis is an inflammation of the pancreas. Symptoms include nausea, vomiting, tenderness when touching the abdomen, weight loss, and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen, and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain. The Pancreatitis drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewNon Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2024
Empower your strategies with our Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) – Drugs In Development, 2024 report and make more profitable business decisions. Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Most people with NAFLD experience no signs and symptoms and no complications, but in some people with the disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are...